Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betacetylmethadol is a synthetic opioid analgesic and a diastereoisomer of alphacetylmethadol and levacetylmethadol. It acts as a narcotic analgesic with a long onset and duration of action. Betacetylmethadol has been investigated mainly for the treatment of narcotic dependence but is not approved for medical use in the United States or other major markets. It is classified as an experimental and illicit substance with no currently accepted medical use due to its high potential for abuse. Mechanistically, like other opioids in its class, it acts primarily as an agonist at opioid receptors[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betacetylmethadol.